Top

Journal of Translational Medicine

Published in:

Open Access 01-12-2012 | Research

Effects of adjuvants on IgG subclasses elicited by virus-like Particles

Authors: Maria Luisa Visciano, Maria Tagliamonte, Maria Lina Tornesello, Franco M Buonaguro, Luigi Buonaguro

Published in: Journal of Translational Medicine | Issue 1/2012

Abstract

Background

Virus-Like Particles (VLPs) represent an efficient strategy to present and deliver conformational antigens to the immune system, inducing both arms of the adaptive immune response. Moreover, their particulate structure surrounded by cell membrane provides an adjuvanted effect to VLP-based immunizations. In the present study, the elicitation of different patterns of IgG subclasses by VLPs, administered in CpG ODN1826 or poly(I:C) adjuvants, has been evaluated in an animal model.

Results

Adjuvanted VLPs elicited a higher titer of total specific IgG compared to VLPs alone. Furthermore, while VLPs alone induced a balanced T_H2 pattern, VLPs formulated with either adjuvant elicited a T_H1-biased IgG subclasses (IgG2a and IgG3), with poly(I:C) more potent than CpG ODN1826.

Conclusions

The results confirmed that adjuvants efficiently improve antigen immunogenicity and represent a suitable strategy to skew the adaptive immune response toward the differentiation of the desired T helper subset, also using VLPs as antigen.

Available only for authorised users

Ross AL, Brave A, Scarlatti G, Manrique A, Buonaguro L: Progress towards development of an HIV vaccine: report of the AIDS Vaccine 2009 Conference. Lancet Infect Dis. 2010, 10: 305-316. 10.1016/S1473-3099(10)70069-4.CrossRefPubMed

Buonaguro L, Tornesello ML, Buonaguro FM: Virus-Like Particles as Particulate Vaccines. Curr HIV Res. 2010, 8: 299-399. 10.2174/157016210791208659.CrossRefPubMed

Bachmann MF, Lutz MB, Layton GT, Harris SJ, Fehr T, Rescigno M, Ricciardi-Castagnoli P: Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol. 1996, 26: 2595-2600. 10.1002/eji.1830261109.CrossRefPubMed

Ruedl C, Storni T, Lechner F, Bachi T, Bachmann MF: Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol. 2002, 32: 818-825. 10.1002/1521-4141(200203)32:3<818::AID-IMMU818>3.0.CO;2-U.CrossRefPubMed

Buonaguro FM, Tornesello ML, Buonaguro L: Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines. 2009, 8: 1379-1398. 10.1586/erv.09.81.CrossRefPubMed

Andre FE, Safary A: Summary of clinical findings on Engerix-B, a genetically engineered yeast derived hepatitis B vaccine. Postgrad Med J. 1987, 63 (Suppl 2): 169-177.PubMed

Harper DM: Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009, 8: 1663-1679. 10.1586/erv.09.123.CrossRefPubMed

Harper DM: Preliminary HPV vaccine results for women older than 25 years. Lancet. 2009, 373: 1921-1922. 10.1016/S0140-6736(09)61045-X.CrossRefPubMed

Grgacic EV, Anderson DA: Virus-like particles: passport to immune recognition. Methods. 2006, 40: 60-65. 10.1016/j.ymeth.2006.07.018.CrossRefPubMed

10.

Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM: Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008, 3: e1501-10.1371/journal.pone.0001501.CrossRefPubMedPubMedCentral

11.

Deml L, Speth C, Dierich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol. 2005, 42: 259-277. 10.1016/j.molimm.2004.06.028.CrossRefPubMed

12.

Young KR, McBurney SP, Karkhanis LU, Ross TM: Virus-like particles: designing an effective AIDS vaccine. Methods. 2006, 40: 98-117. 10.1016/j.ymeth.2006.05.024.CrossRefPubMed

13.

Buonaguro L, Visciano ML, Tornesello ML, Tagliamonte M, Biryahwaho B, Buonaguro FM: Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J Virol. 2005, 79: 7059-7067. 10.1128/JVI.79.11.7059-7067.2005.CrossRefPubMedPubMedCentral

14.

Buonaguro L, Devito C, Tornesello ML, Schroder U, Wahren B, Hinkula J, Buonaguro FM: DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity. Vaccine. 2007, 25: 5968-5977. 10.1016/j.vaccine.2007.05.052.CrossRefPubMed

15.

Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ: Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci USA. 2003, 100: 6753-6758. 10.1073/pnas.1131929100.CrossRefPubMedPubMedCentral

16.

Hammarstrom L, Smith CI: IgG subclasses in bacterial infections. Monogr Allergy. 1986, 19: 122-133.PubMed

17.

Linde A, Sundqvist VA, Mathiesen T, Wahren B: IgG subclasses to subviral components. Monogr Allergy. 1988, 23: 27-32.PubMed

18.

Ferrante A, Beard LJ, Feldman RG: IgG subclass distribution of antibodies to bacterial and viral antigens. Pediatr Infect Dis J. 1990, 9: S16-S24.PubMed

19.

Powers DC: Effect of age on serum immunoglobulin G subclass antibody responses to inactivated influenza virus vaccine. J Med Virol. 1994, 43: 57-61. 10.1002/jmv.1890430111.CrossRefPubMed

20.

Sanders LA, Rijkers GT, Tenbergen-Meekes AM, Voorhorst-Ogink MM, Zegers BJ: Immunoglobulin isotype-specific antibody responses to pneumococcal polysaccharide vaccine in patients with recurrent bacterial respiratory tract infections. Pediatr Res. 1995, 37: 812-819. 10.1203/00006450-199506000-00023.CrossRefPubMed

21.

Adderson EE, Shackelford PG, Quinn A, Carroll WL: Restricted Ig H chain V gene usage in the human antibody response to Haemophilus influenzae type b capsular polysaccharide. J Immunol. 1991, 147: 1667-1674.PubMed

22.

Adderson EE, Shackelford PG, Quinn A, Wilson PM, Cunningham MW, Insel RA, Carroll WL: Restricted immunoglobulin VH usage and VDJ combinations in the human response to Haemophilus influenzae type b capsular polysaccharide. Nucleotide sequences of monospecific anti-Haemophilus antibodies and polyspecific antibodies cross-reacting with self antigens. J Clin Invest. 1993, 91: 2734-2743. 10.1172/JCI116514.CrossRefPubMedPubMedCentral

23.

Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G: Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med. 1980, 303: 178-182. 10.1056/NEJM198007243030402.CrossRefPubMed

24.

Bachmann MF, Zinkernagel RM: The influence of virus structure on antibody responses and virus serotype formation. Immunol Today. 1996, 17: 553-558. 10.1016/S0167-5699(96)10066-9.CrossRefPubMed

25.

Schumaker VN, Calcott MA, Spiegelberg HL, Muller-Eberhard HJ: Ultracentifuge studies of the binding of IgG of different subclasses to the Clq subunit of the first component of complement. Biochemistry. 1976, 15: 5175-5181. 10.1021/bi00668a035.CrossRefPubMed

26.

Anderson CL, Loone RJ: Human leukocyte IgG Fc receptors. Immunology Today. 1986, 7 (9): 264-266. 10.1016/0167-5699(86)90007-1. Ref Type: Journal (Full)CrossRefPubMed

27.

Snapper CM, Finkelman FD: Immunoglobulin class switching. Fundamental Immunology. Edited by: Paul WE. 1999, Philadelphia: Lippincott-Raven, 831-

28.

Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP: IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines. AIDS Res Hum Retroviruses. 2010, 26: 445-458. 10.1089/aid.2009.0223.CrossRefPubMedPubMedCentral

29.

Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, Clauvel JP, Agut H, Costagliola D, Rouzioux C: HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res Hum Retroviruses. 2001, 17: 1435-1446. 10.1089/088922201753197105.CrossRefPubMed

30.

Sundqvist VA, Linde A, Kurth R, Werner A, Helm EB, Popovic M, Gallo RC, Wahren B: Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis. 1986, 153: 970-973. 10.1093/infdis/153.5.970.CrossRefPubMed

31.

Gorse GJ, Patel GB, Mandava M, Berman PW, Belshe RB: MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1999, 15: 921-930. 10.1089/088922299310638.CrossRefPubMed

32.

Jankovic D, Caspar P, Zweig M, Garcia-Moll M, Showalter SD, Vogel FR, Sher A: Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. J Immunol. 1997, 159: 2409-2417.PubMed

33.

Visciano ML, Tuen M, Gorny MK, Hioe CE: In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology. 2008, 372: 409-420. 10.1016/j.virol.2007.10.044.CrossRefPubMedPubMedCentral

34.

Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, Michael E, Durso RJ, Ketas TJ, Olson WC, Moore JP: Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology. 2009, 389: 108-121. 10.1016/j.virol.2009.04.001.CrossRefPubMedPubMedCentral

35.

Chin'ombe N, Bourn WR, Williamson AL, Shephard EG: Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice. Virol J. 2009, 6: 87-10.1186/1743-422X-6-87.CrossRefPubMedPubMedCentral

36.

Bielinska AU, Janczak KW, Landers JJ, Markovitz DM, Montefiori DC, Baker JR: Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses. 2008, 24: 271-281. 10.1089/aid.2007.0148.CrossRefPubMed

37.

Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA: Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses. J Immunol. 2005, 174: 7676-7683.CrossRefPubMed

38.

Davis HL, Weeratna R, Waldschmidt TJ, Tygrett L, Schorr J, Krieg AM: CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol. 1998, 160: 870-876.PubMed

39.

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A Toll-like receptor recognizes bacterial DNA. Nature. 2000, 408: 740-745. 10.1038/35047123.CrossRefPubMed

40.

Baker PJ, Hiernaux JR, Fauntleroy MB, Stashak PW, Prescott B, Cantrell JL, Rudbach JA: Ability of monophosphoryl lipid A to augment the antibody response of young mice. Infect Immun. 1988, 56: 3064-3066.PubMedPubMedCentral

41.

Weeratna RD, Brazolot Millan CL, McCluskie MJ, Davis HL: CpG ODN can re-direct the Th bias of established Th2 immune responses in adult and young mice. FEMS Immunol Med Microbiol. 2001, 32: 65-71. 10.1111/j.1574-695X.2001.tb00535.x.CrossRefPubMed

42.

Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, Trumpfheller C, Salazar AM, Uberla K, Nieto K, Kleinschmidt J, Schulte R, Gissmann L, Muller M, Sacher A, Racz P, Steinman RM, Uguccioni M, Ignatius R: Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog. 2009, 5: e1000373-10.1371/journal.ppat.1000373.CrossRefPubMedPubMedCentral

43.

Wuorimaa T, Dagan R, Vakevainen M, Bailleux F, Haikala R, Yaich M, Eskola J, Kayhty H: Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis. 2001, 184: 1211-1215. 10.1086/323648.CrossRefPubMed

44.

Lefeber DJ, aissa-Trouw B, Vliegenthart JF, Kamerling JP, Jansen WT, Kraaijeveld K, Snippe H: Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3. Infect Immun. 2003, 71: 6915-6920. 10.1128/IAI.71.12.6915-6920.2003.CrossRefPubMedPubMedCentral

45.

Buonaguro L, Del Gaudio E, Monaco M, Greco D, Corti P, Beth-Giraldo E, Buonaguro FM, Giraldo G: Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of HIV 1 isolates from Gulu-Northern Uganda. J Virol. 1995, 69: 7971-7981.PubMedPubMedCentral

46.

Buonaguro L, Buonaguro FM, Russo F, Tornesello ML, Beth-Giraldo E, Wagner R, Wolf H, Giraldo G: A novel gp120 sequence from an HIV-1 isolate of the A clade identified in North Uganda. AIDS Res Hum Retroviruses. 1998, 14: 1287-1289. 10.1089/aid.1998.14.1287.CrossRefPubMed

47.

Buonaguro L, Buonaguro FM, Tornesello ML, Mantas D, Beth-Giraldo E, Wagner R, Michelson S, Prevost M-C, Wolf H, Giraldo G: High efficient production of Pr55gag Virus-like Particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Research. 2001, 49: 35-47. 10.1016/S0166-3542(00)00136-4.CrossRefPubMed

48.

Tagliamonte M, Visciano ML, Tornesello ML, De SA, Buonaguro FM, Buonaguro L: HIV-Gag VLPs presenting trimeric HIV-1 gp140 spikes constitutively expressed in stable double transfected insect cell line. Vaccine. 2011

49.

Buonaguro L, Racioppi L, Tornesello ML, Arra C, Visciano ML, Biryahwaho B, Sempala SDK, Giraldo G, Buonaguro FM: Induction of neutralizing antibodies and CTLs in Balb/c mice immunized with Virus-like Particles presenting a gp120 molecule from a HIV-1 isolate of clade A (HIV-VLPAs). Antiviral Research. 2002, 54: 189-201. 10.1016/S0166-3542(02)00004-9.CrossRefPubMed

50.

Visciano ML, Diomede L, Tagliamonte M, Tornesello ML, Asti V, Bomsel M, Buonaguro FM, Lopalco L, Buonaguro L: Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins. Vaccine. 2011

51.

Aricò E, Wang E, Tornesello ML, Tagliamonte M, Lewis GK, Marincola FM, Buonaguro FM, Buonaguro L: Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med. 2005, 3: 45-10.1186/1479-5876-3-45.CrossRefPubMedPubMedCentral

52.

Buonaguro L, Monaco A, Arico E, Wang E, Tornesello ML, Lewis GK, Marincola FM, Buonaguro FM: Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics. 2008, 9 (Suppl 2): S5-10.1186/1471-2105-9-S2-S5.CrossRefPubMedPubMedCentral

53.

Buonaguro L, Tornesello ML, Gallo RC, Marincola FM, Lewis GK, Buonaguro FM: Th2 Polarization in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus (HIV)-Infected Subjects, as Activated by HIV Virus-Like Particles. J Virol. 2009, 83: 304-313. 10.1128/JVI.01606-08.CrossRefPubMedPubMedCentral

54.

Buonaguro L, Tornesello ML, Jewis GK, Buonaguro FM: Short communication: limited induction of IL-10 in PBMCs from HIV-infected subjects treated with HIV-VLPs. AIDS Res Hum Retroviruses. 2009, 25: 819-822. 10.1089/aid.2008.0304.CrossRefPubMedPubMedCentral

55.

Klinman DM, Currie D, Gursel I, Verthelyi D: Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev. 2004, 199: 201-216. 10.1111/j.0105-2896.2004.00148.x.CrossRefPubMed

56.

Klinman DM: Adjuvant activity of CpG oligodeoxynucleotides. Int Rev Immunol. 2006, 25: 135-154. 10.1080/08830180600743057.CrossRefPubMed

57.

Jin B, Sun T, Yu XH, Liu CQ, Yang YX, Lu P, Fu SF, Qiu HB, Yeo AE: Immunomodulatory effects of dsRNA and its potential as vaccine adjuvant. J Biomed Biotechnol. 2010, 2010: 690438-CrossRefPubMedPubMedCentral

58.

Meylan E, Tschopp J: Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell. 2006, 22: 561-569. 10.1016/j.molcel.2006.05.012.CrossRefPubMed

59.

Matsumoto M, Seya T: TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev. 2008, 60: 805-812. 10.1016/j.addr.2007.11.005.CrossRefPubMed

60.

Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, Kluger C, Salazar AM, Colonna M, Steinman RM: Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med. 2009, 206: 1589-1602. 10.1084/jem.20090247.CrossRefPubMedPubMedCentral

61.

Le Bon A, Thompson C, Kamphuis E, Durand V, Rossmann C, Kalinke U, Tough DF: Cutting edge: enhancement of antibody responses through direct stimulation of B and T cells by type I IFN. J Immunol. 2006, 176: 2074-2078.CrossRefPubMed

62.

Tewari K, Flynn BJ, Boscardin SB, Kastenmueller K, Salazar AM, Anderson CA, Soundarapandian V, Ahumada A, Keler T, Hoffman SL, Nussenzweig MC, Steinman RM, Seder RA: Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine. 2010, 28: 7256-7266. 10.1016/j.vaccine.2010.08.098.CrossRefPubMedPubMedCentral

63.

Le BA, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D, Borrow P, Tough DF: Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol. 2003, 4: 1009-1015.CrossRef

64.

Le BA, Durand V, Kamphuis E, Thompson C, Bulfone-Paus S, Rossmann C, Kalinke U, Tough DF: Direct stimulation of T cells by type I IFN enhances the CD8+ T cell response during cross-priming. J Immunol. 2006, 176: 4682-4689.CrossRef

65.

Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995, 374: 546-549. 10.1038/374546a0.CrossRefPubMed

66.

Verthelyi D, Zeuner RA: Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 2003, 24: 519-522. 10.1016/S1471-4906(03)00243-6.CrossRefPubMed

67.

Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci USA. 1996, 93: 2879-2883. 10.1073/pnas.93.7.2879.CrossRefPubMedPubMedCentral

68.

Sun S, Zhang X, Tough DF, Sprent J: Type I interferon-mediated stimulation of T cells by CpG DNA. J Exp Med. 1998, 188: 2335-2342. 10.1084/jem.188.12.2335.CrossRefPubMedPubMedCentral

69.

Stacey KJ, Sweet MJ, Hume DA: Macrophages ingest and are activated by bacterial DNA. J Immunol. 1996, 157: 2116-2122.PubMed

70.

Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996, 157: 1840-1845.PubMed

71.

Roman M, Martin-Orozco E, Goodman JS, Nguyen MD, Sato Y, Ronaghy A, Kornbluth RS, Richman DD, Carson DA, Raz E: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med. 1997, 3: 849-854. 10.1038/nm0897-849.CrossRefPubMed

72.

73.

Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol. 1996, 157: 1840-1845.PubMed

74.

75.

Halpern MD, Kurlander RJ, Pisetsky DS: Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. Cell Immunol. 1996, 167: 72-78. 10.1006/cimm.1996.0009.CrossRefPubMed

76.

Gupta RK, Siber GR: Adjuvants for human vaccines--current status, problems and future prospects. Vaccine. 1995, 13: 1263-1276. 10.1016/0264-410X(95)00011-O.CrossRefPubMed

77.

Krieg AM: Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta. 1999, 1489: 107-116.CrossRefPubMed

78.

McCluskie MJ, Davis HL: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol. 1998, 161: 4463-4466.PubMed

79.

80.

Rovinski B, Haynes JR, Cao SX, James O, Sia C, Zolla-Pazner S, Matthews TJ, Klein MH: Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross- protective AIDS vaccine. J Virol. 1992, 66: 4003-4012.PubMedPubMedCentral

81.

82.

McIntyre TM, Klinman DR, Rothman P, Lugo M, Dasch JR, Mond JJ, Snapper CM: Transforming growth factor beta 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J Exp Med. 1993, 177: 1031-1037. 10.1084/jem.177.4.1031.CrossRefPubMed

83.

Weiner HL: Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect. 2001, 3: 947-954. 10.1016/S1286-4579(01)01456-3.CrossRefPubMed

84.

Martinez V, Costagliola D, Bonduelle O, N'go N, Schnuriger A, Theodorou I, Clauvel JP, Sicard D, Agut H, Debre P, Rouzioux C, Autran B: Combination of HIV-1-specific CD4 Th1 cell responses and IgG2 antibodies is the best predictor for persistence of long-term nonprogression. J Infect Dis. 2005, 191: 2053-2063. 10.1086/430320.CrossRefPubMed

85.

Le BA, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, Tough DF: Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 2001, 14: 461-470. 10.1016/S1074-7613(01)00126-1.CrossRef

86.

Swanson CL, Wilson TJ, Strauch P, Colonna M, Pelanda R, Torres RM: Type I IFN enhances follicular B cell contribution to the T cell-independent antibody response. J Exp Med. 2010, 207: 1485-1500. 10.1084/jem.20092695.CrossRefPubMedPubMedCentral

87.

Scharf O, Golding H, King LR, Eller N, Frazier D, Golding B, Scott DE: Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1. J Virol. 2001, 75: 6558-6565. 10.1128/JVI.75.14.6558-6565.2001.CrossRefPubMedPubMedCentral

88.

Gray ES, Madiga MC, Moore PL, Mlisana K, bdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L: Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol. 2009, 83: 11265-11274. 10.1128/JVI.01359-09.CrossRefPubMedPubMedCentral

89.

Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA: Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA. 2010, 107: 11483-11488. 10.1073/pnas.1004600107.CrossRefPubMedPubMedCentral

90.

Saphire EO, Parren PW, Barbas CF, Burton DR, Wilson IA: Crystallization and preliminary structure determination of an intact human immunoglobulin, b12: an antibody that broadly neutralizes primary isolates of HIV-1. Acta Crystallogr D Biol Crystallogr. 2001, 57: 168-171. 10.1107/S0907444900017376.CrossRefPubMed

91.

Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA: Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science. 2003, 300: 2065-2071. 10.1126/science.1083182.CrossRefPubMed

92.

Vogel FR: Improving vaccine performance with adjuvants. Clin Infect Dis. 2000, 30 (Suppl 3): S266-S270.CrossRefPubMed

Title: Effects of adjuvants on IgG subclasses elicited by virus-like Particles
Authors: Maria Luisa Visciano
Maria Tagliamonte
Maria Lina Tornesello
Franco M Buonaguro
Luigi Buonaguro
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/1479-5876-10-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of adjuvants on IgG subclasses elicited by virus-like Particles

Abstract

Background

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

CD20-negative de novo diffuse large B-cell lymphoma in HIV-negative patients: A matched case-control analysis in a single institution

The immune score as a new possible approach for the classification of cancer

Further evidence for the existence of major susceptibility of nasopharyngeal carcinoma in the region near HLA-A locus in Southern Chinese

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome

Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

Novel classes of non-coding RNAs and cancer

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page